Collaborations, Licensing and Other Arrangements - Additional Information (Detail) - USD ($)		1 Months Ended			12 Months Ended
	Oct. 31, 2018	Aug. 31, 2025	Dec. 31, 2023	May 31, 2018	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue			$ 78,879,000		$ 55,308,000	$ 63,567,000	$ 78,879,000	$ 63,567,000
Deferred revenue - current					15,331,000	12,407,000
Deferred revenue - non-current					39,977,000	51,160,000
Total revenue from UT					348,966,000	285,504,000	198,962,000
Amphastar
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Performance obligation transaction price						2,500,000
Performance obligation transaction price recognized					2,000,000	500,000
Cipla Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT					600,000
Manufacturing Services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT					1,600,000	7,100,000	0
Collaborations and services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT					106,713,000	100,840,000	52,954,000
AFREZZA product sales
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT					114,137,000	82,329,000	74,029,000
United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT					231,501,000	201,428,000	124,786,000
United Therapeutics Corporation | Facility Expansion Services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue					$ 52,200,000	52,200,000
Collaboration and License Agreement | United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalty percentage	10.00%				10.00%
Royalty future net sales percentage			1.00%
Royalty retaining percentage			9.00%
License agreement description					There have been various amendments to the CSA since inception. As amended, the term of the CSA continues until December 31, 2031 (unless earlier terminated) and is thereafter renewed automatically for additional, successive two-year terms unless (i) UT provides notice to the Company at least 24 months in advance of such renewal that UT does not wish to renew the CSA or (ii) the Company provides notice to UT at least 48 months in advance of such renewal that the Company does not wish to renew the CSA.
Deferred revenue					$ 55,300,000	62,400,000
Deferred revenue - current					15,300,000	12,300,000
Deferred revenue - non-current					40,000,000	50,100,000
Collaboration and License Agreement | United Therapeutics Corporation | Other Administrative Services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue					61,300,000	61,300,000
Commercial Supply Agreement | United Therapeutics Corporation | Collaborations and services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT					102,385,000	96,228,000	52,025,000
Co-Promotion Agreement | Collaborations and services | Amphastar
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT					2,000,000	500,000
UT License Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received		$ 5,000,000
Development milestones		$ 35,000,000
Percentage of royalty on net sales		10.00%
Deferred revenue - current					4,000,000
Total revenue from UT					1,000,000
UT License Agreement | Current Stage of Development and Achievement Criteria
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestones		$ 10,000,000
UT License Agreement | Constrained
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Development milestones		$ 30,000,000
License and Distribution Agreement | Cipla Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments						1,100,000
Revenue recognized during period					1,200,000
Deferred revenue						1,200,000
Deferred revenue - current						100,000
Deferred revenue - non-current						1,100,000
Marketing and distribution agreement date				2018-05
License and Distribution Agreement | Collaborations and services | Cipla Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT					$ 1,222,000	1,247,000	147,000
License and Distribution Agreement | Nonrefundable Licensing Fee
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue						2,200,000
License and Distribution Agreement | India | Collaborations and services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT						$ 0	$ 0